Grainyheadlike 2 distribution reveals novel pathophysiological differences between human idiopathic pulmonary fibrosis and mouse models of pulmonary fibrosis by Varma, Saaket et al.
CALL FOR PAPERS Translational Research in Acute Lung Injury and Pulmonary
Fibrosis
Grainyhead-like 2 (GRHL2) distribution reveals novel pathophysiological
differences between human idiopathic pulmonary fibrosis and mouse models
of pulmonary fibrosis
Saaket Varma,1 Poornima Mahavadi,2 Satish Sasikumar,1 Leah Cushing,3 Tessa Hyland,1 Ann E. Rosser,4
Daniela Riccardi,5 Jining Lu,3 Tanya V. Kalin,6 Vladimir V. Kalinichenko,6 Andreas Guenther,2,7
Maria I. Ramirez,3 Annie Pardo,8 Moisés Selman,9 and David Warburton1
1Saban Research Institute, Children’s Hospital Los Angeles, Keck School of Medicine University of Southern California, Los
Angeles, California; 2University of Giessen and Marburg Lung Center, Department of Internal Medicine II, German Lung
Research Center (DZL), Giessen, Germany; 3Pulmonary Center, Department of Medicine, Boston University School of
Medicine, Boston, Massachusetts; 4Cardiff & Vale University Health Board, Llandough Hospital, Cardiff, United Kingdom;
5School of Biosciences, Cardiff University, Cardiff, United Kingdom; 6Pulmonary Biology, Cincinnati Children’s Hospital
Medical Center, Cincinnati, Ohio; 7Agaplesion Lung Clinic Waldhof-Elgerhausen, Griefenstein, Germany; 8Universidad
Nacional Autónoma de México, Mexico City, Mexico; and 9Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío
Villegas, México DF, México
Submitted 4 June 2013; accepted in final form 18 December 2013
Varma S, Mahavadi P, Sasikumar S, Cushing L, Hyland T,
Rosser AE, Riccardi D, Lu J, Kalin TV, Kalinichenko VV, Guen-
ther A, Ramirez MI, Pardo A, Selman M, Warburton D. Grainy-
head-like 2 (GRHL2) distribution reveals novel pathophysiological
differences between human idiopathic pulmonary fibrosis and
mouse models of pulmonary fibrosis. Am J Physiol Lung Cell Mol
Physiol 306: L405–L419, 2014. First published December 27,
2013; doi:10.1152/ajplung.00143.2013.—Chronic injury of alveolar
lung epithelium leads to epithelial disintegrity in idiopathic pulmo-
nary fibrosis (IPF). We had reported earlier that Grhl2, a transcrip-
tional factor, maintains alveolar epithelial cell integrity by directly
regulating components of adherens and tight junctions and thus
hypothesized an important role of GRHL2 in pathogenesis of IPF.
Comparison of GRHL2 distribution at different stages of human lung
development showed its abundance in developing lung epithelium and
in adult lung epithelium. However, GRHL2 is detected in normal
human lung mesenchyme only at early fetal stage (week 9). Similar
mesenchymal reexpression of GRHL2 was also observed in IPF.
Immunofluorescence analysis in serial sections from three IPF pa-
tients revealed at least two subsets of alveolar epithelial cells (AEC),
based on differential GRHL2 expression and the converse fluores-
cence intensities for epithelial vs. mesenchymal markers. Grhl2 was
not detected in mesenchyme in intraperitoneal bleomycin-induced
injury as well as in spontaneously occurring fibrosis in double-mutant
HPS1 and HPS2 mice, whereas in contrast in a radiation-induced
fibrosis model, with forced Forkhead box M1 (Foxm1) expression, an
overlap of Grhl2 with a mesenchymal marker was observed in fibrotic
regions. Grhl2’s role in alveolar epithelial cell plasticity was con-
firmed by altered Grhl2 gene expression analysis in IPF and further
validated by in vitro manipulation of its expression in alveolar
epithelial cell lines. Our findings reveal important pathophysiological
differences between human IPF and specific mouse models of fibrosis
and support a crucial role of GRHL2 in epithelial activation in lung
fibrosis and perhaps also in epithelial plasticity.
GRHL2; idiopathic pulmonary fibrosis; epithelial integrity; cell flat-
tening; epithelial plasticity
IDIOPATHIC PULMONARY FIBROSIS (IPF) is an age-related chronic
lung disease of unknown cause that has a poor prognosis and
few treatment options (10, 17, 20, 26, 29, 33). IPF was once
thought to be the result of a chronic inflammatory process, but
current evidence indicates that the fibrotic response in this
disease is driven by chronic injury and activation of type II
alveolar epithelial cells (AEC) (30, 31). Thus injured and
activated AECs produce a variety of mediators that may induce
the expansion of fibroblast populations and their differentiation
to myofibroblasts, which organize into characteristic clusters
called fibroblast/myofibroblast foci. The origin of fibroblasts in
IPF is still under vigorous debate but may include the migra-
tion and proliferation of resident mesenchymal cells and/or
recruitment of bone marrow-derived cells such as circulating
fibrocytes. A growing body of evidence also indicates a role of
epithelial-mesenchymal plasticity, which has been termed “ep-
ithelial cell-flattening events” (31, 34). Histological analyses
have suggested that AEC can undergo cell flattening and cell
elongation, events that may precede a transition into a fibro-
blastic and eventually a myofibroblastic phenotype (31).
Lung fibrosis has been studied extensively in mouse models
such as intratracheal (IT) (11, 12) or intraperitoneal (IP)
administration of bleomycin (9). Administration of bleomycin
results in marked but eventually transient lung fibrosis, prom-
inent alveolar epithelial cell hyperplasia, with a pattern of
spatial and temporal heterogeneity, and persistence of aberrant
remodeling well after the bleomycin treatment. But there are
marked differences in lung injury pattern between the IT vs. IP
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routes of administration of bleomycin. Whereas in the IT
model an extensive inflammation response precedes the fibrotic
response, IP bleomycin elicits mainly an injury to alveolar
epithelium and endothelium with less marked inflammatory
responses. In contrast, spontaneous pulmonary fibrosis occurs
in Hermansky-Pudlak syndrome (HPS mutant) mice (23, 24).
HPS is a rare inherited disease affecting intracellular biogen-
esis of lysosome-related organelles (13). Individual mutations
in HPS1 or HPS2 make these mice highly susceptible to
bleomycin-induced injury-induced lung fibrosis, whereas dou-
ble-mutant HPS1 and HPS2 (HPS1/2) mice develop spontaneous
pulmonary fibrosis (14). Recently a radiation-induced injury
model, in which Foxm1 was overexpressed, showed spontaneous
pneumonitis and pulmonary fibrosis with increased expression of
both interleukins and epithelial-to-mesenchymal (EMT) marker
transcriptional factors such as ZEB1 (4).
The Grainyhead-like (GRHL) gene family comprises GRHL1,
GRHL2, and GRHL3, which function as wound healing and
injury repair genes in cutaneous tissue in Drosophila and
mouse (14, 36). However, their functional role in injury repair
in the lung is not yet fully understood. Among the Grainyhead
family members, Grhl2 is the most abundant and universally
expressed in mouse lung epithelium during lung development
(2, 40, 41). We recently characterized the expression pattern of
Grhl2 during lung development and showed that this gene is
highly expressed very early during lung development and also
in adult mouse alveolar and bronchial lung epithelium (40, 41).
We also found that Grhl2 colocalizes with Nkx2.1 in lung
epithelium and that these genes interact in a positive feedback
loop to maintain lung epithelial cell integrity, cell identity,
collective cell migration, and cell-cell interactions (40, 41). We
further showed that Grhl2 knockdown in the alveolar type
II-like MLE15 cell line resulted in cell-flattening events, with
alteration in distribution of F-actin filaments. Moreover, we
also suggested that the expression of Tert, which is an impor-
tant injury repair gene, may be regulated by Grhl2 in alveolar
epithelium, which corroborates another study showing that
GRHL2 mediates epigenetic regulation of TERT in human
keratinocytes (5, 6, 19). The fact that mutation in TERT is
known to predispose to familial IPF (1, 22, 38) suggests a
possible functional role of GRHL2 in the pathogenesis of IPF.
Herein, we have compared the distribution of GRHL2 im-
munofluorescence signal in normal human vs. IPF lungs with
that observed in three mouse models of lung fibrosis: 1) IP
bleomycin-induced lung injury and fibrosis, 2) spontaneously
occurring pulmonary fibrosis in HPS1/2 mutants, and 3) radi-
ation-induced lung injury in which Foxm1 is misexpressed. We
observed that GRHL2 is ectopically expressed in IPF lung
mesenchyme, although at a relatively low level compared with
lung epithelium. This distribution of GRHL2 was similar to
that found in human lung at embryonic week 9. In alveolar
epithelium of IPF lung we also observed at least two subsets of
AEC, one showing bright GRHL2 and ABCA3 fluorescence
and the other showing a dimmer fluorescence level. On the
basis of double staining in serial sections with EMT markers
and GRHL2, we showed that the second dimmer set of AEC
appeared to be undergoing cell flattening. Furthermore, overall
GRHL2 expression was low in fibrotic areas of IPF lung
compared with control donors, whereas in vitro knockdown vs.
overexpression of Grhl2 in lung epithelial cells confirmed its
potential role in epithelial to mesenchymal plasticity. We also
observed similar cell-flattening events in alveolar epithelium in
the radiation induced fibrosis model with Foxm1 misexpres-
sion, but neither in IP bleomycin-induced nor in spontaneously
occurring pulmonary fibrosis in HPS1/2 mutant mice, thus
revealing novel and important contrasting pathophysiological
phenotypic differences between human IPF and these specific
mouse models of pulmonary fibrosis.
MATERIALS AND METHODS
Lung tissue sections from human and mice. Sections of deidentified
histologically normal lung tissue (n  2) and from IPF lungs (n  3)
were kindly provided in collaboration by Dr. Moises Selman. IPF lung
samples were obtained from patients undergoing open lung biopsy for
diagnosis purposes (63  3 yr; two former smokers and one a lifetime
nonsmoker), and the diagnosis was established according the Amer-
ican Thoracic Society/European Respiratory Society criteria including
characteristic histological features of usual interstitial pneumonia
(27). IPF patients had never been treated with corticosteroids or
immunosuppressive drugs at the time of the biopsy. This study was
approved by the Science and Bioethical Committee at the National
Institute of Respiratory Diseases. For gene expression studies primary
reverse transcription stage samples from IPF patients (n  11) and
normal donor (n  8) were also supplied in collaboration with Dr.
Andreas Guenther and Dr. Moises Selman. Normal adult lung tissue
sections were obtained from Biochain (no. T2234152) as well as lung
sections from a 38-wk human fetus. Human early fetal lung tissue was
obtained from maternal donors undergoing elective termination at
8–11 wk of pregnancy in collaboration with Dr. Daniela Riccardi and
colleagues at Cardiff. Gestational age was assessed by ultrasound
measurements and confirmed by using fetal morphometric parameters
after medical termination of pregnancy. Following dissections, lungs
were fixed in 4% paraformaldehyde overnight and paraffin embedded,
and 8-mm sections were used for immunofluorescence. Lung sections
from the following mouse models were processed as follows: HPS1/2
mouse (14-mo-old) and BL/6J (12-mo-old) lung sections were pro-
cessed as described earlier by Mahavadi et al. (23, 24). Bleomycin-
induced injury lung sections were processed as described earlier by
Cushing et al. (9). For radiation-induced lung injury model, epithelial-
specific Foxm1-overexpressing mice (Spc-rtTAtg//tetO-Foxm1-
Ntg/-epiFoxm1-N) were described previously (3, 4). For radia-
tion-induced fibrosis studies, thoracic contents of epiFoxm1-N and
littermate control mice were irradiated with a single dose of 12 Gy by
use of a 137Cs Mark I-68A irradiator (J. L. Shepard and Associates,
San Fernando, CA) at a dose rate of 0.725 Gy per min. Mice were
anesthetized and placed in lead shielding to protect all parts of the
body except the thoracic region. Lungs were isolated, fixed, and
embedded into paraffin blocks or were used for total lung RNA with
RNA-stat-60 (Tel-Test “B”) at 6 mo postradiation.
RNA purification and qRT-PCR. Total RNA was isolated from
mouse lung tissue, sorted cells and cell lines using an RNeasy kit
(Qiagen) and treated with DNase1 (Qiagen). Isolated RNA was
reverse transcribed by using TaqMan Reverse Transcription Reagents
(Applied Biosystems) or Omniscript RT kit (Qiagen) following the
manufacturer’s protocols. A StepOnePlus system (Applied Biosys-
tems) using TaqMan gene expression assays (Applied Biosystems)
was used for quantitative RT-PCR (qRT-PCR) analyses (data avail-
able on request). Reactions were performed with TaqMan PCR master
mix or Fast TaqMan PCR master mix (Applied Biosystems) or with
SYBR green PCR master mix. Relative expression levels were deter-
mined by the comparative 2CT method, normalized to Gapdh.
Plasmid construction. Full-length Grhl2 cDNA was subcloned
from the pGADT7-HA-Grhl2 vector provided by Dr. Bogi Anderson
(University of California, Irvine, CA). Cloning is described in our
previous publication (40). Briefly, the Grhl2 cDNA was amplified
by PCR using primers 5=-CAAGCGGCCGCCATGTCACAAGAGT-
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CGGAC-3= and 5=CGCTGATGGAGATCTGAGGATCCATTC-3=,
which contain Not1 and BamH1 sites, respectively. This fragment was
then inserted in place of the DsRed gene in the dual promoter-reporter
lentiviral plasmid, pCMV-dsred-UBC-GFP (40), to generate pCMV-
Grhl2-UBC-GFP. The construct was verified by restriction enzyme
digestion and by sequencing. This Grhl2 vector was used to overex-
press Grhl2 in flat E10, an adult lung epithelial cell line that expresses
type I cell genes, provided by Dr. A. Malkinson (University of Colorado,
Denver, CO) and Dr. Randy Ruch (Medical College of Ohio).
Lentivirus production and transduction. For Grhl2 knockdown
studies, mission shRNA transduction particles and nontargeting con-
trol shRNA (SHC002V) or Grhl2shRNA (TRCN0000084224) target-
ing Grhl2 were purchased from Sigma Aldrich. MLE15 epithelial cell
transductions with lentiviral vectors were performed for 16 h in the
presence of polybrene (5 g/ml) at a multiplicity of infection of 50.
Stable cell lines were generated by puromycin dihydrochloride (5
g/ml, Sigma) selection for 6 days. Cells were harvested 48 h after
infection and analyzed for transduction efficiency and viability by
flow cytometry analysis of GFP expression and exclusion of pro-
pidium iodide. Knockdown and overexpression of Grhl2 in MLE15
and E10 cells, respectively, were quantified at the mRNA level by
qRT-PCR and at the protein level by immunostaining and Western
blot as described previously in our earlier publication (40).
Immunocytochemistry. E10 cells that were transduced with lenti-
viruses packaged with CMV-GRHL2-UBC-GFP plasmid as described
previously (40) were grown on glass coverslips to reach 70–80%
confluence, fixed with 4% formaldehyde in 1 PBS, and processed
for immunostaining. For GRHL2 nuclear staining, cells were treated
with 0.01% Triton X-100 (Fisher Scientific) in 1 PBS, blocked with
1 PBS containing 2% FBS for 30 min, and incubated overnight at
4°C with rabbit GRHL2 antibody (HPA00482, Sigma; 1:500 dilu-
tion). After three washes with 1 PBS, cells were incubated with
secondary anti-rabbit CY3-conjugated antibody (Invitrogen, 1:2,000
dilution) for 1 h at room temperature. Images were taken on a Leica
inverted microscope. Images were processed with Image J analysis
software.
Immunofluorescence. Human and mouse lung paraffin sections
were processed as described in Ref. 40. Briefly, the sections were
deparaffinized at 55°C for 1 h, cleared in HistoChoice (H2904
Sigma-Aldrich), and hydrated by incubation for 3 min each with 100,
95, and 70% ethanol dilutions and water. Antigen retrieval of the
tissue sections was performed in antigen unmasking solution (H-3300,
Vector Laboratories) and heating them in a microwave oven. The
sections were allowed to cool down to room temperature for 1 h and
subsequently permeabilized by incubating them in 1 TN buffer (20
mM Tris·HCl, pH 7.4, 150 mM NaCl) containing 0.5% Triton X-100
(TNT) at room temperature for 1 h. They were blocked in 1 TN
buffer containing 3% BSA and 0.5% Tween-20 at room temperature
for 30 min. The primary antibodies were then applied to sections and
incubated in a moist chamber at 4°C overnight. The following day, the
sections were washed in 1 TNT for 5 min and then incubated for 1
h with Alexa Fluor-labeled secondary antibodies (Invitrogen) at a
dilution of 1:200. The sections were again washed in 1 TNT for 5
min and mounted with Prolong Gold with DAPI (Invitrogen). The
sections were imaged via a confocal microscope (Zeiss 710) and
processed with ZEN 2009 software (Carl Zeiss). Primary antibodies
and IgG controls used for this study are shown in Table 1. The following
secondary antibodies were employed: donkey anti-rabbit Alexa Fluor
647, donkey anti-mouse Alexa Fluor 647, donkey anti-rabbit Alexa Fluor
488, donkey anti-mouse Alexa Fluor 488 (Invitrogen).
Confocal imaging. Images were acquired via an LSM 710 confocal
system mounted on an AxioObserver.Z1 microscope equipped with a
20/0.8 Plan-APOCHROMAT lens and controlled by ZEN 2010
software (Carl Zeiss Microimaging, Thornwood, NY). Fluorescence
excitation lasers were 405 nm for DAPI, 488 nm for Alexa 488, 561
nm for Cy3, and 633 nm for Alexa 647 dyes. For all dyes the confocal
pinhole was set to 1 Airy unit of Alexa 647. Fluorescence emission
was detected with a spectral array detector and dye fluorescence was
separated from tissue autofluorescence by linear unmixing. To in-
crease the contiguous area that was imaged, the optical zoom factor
was set to 0.6 and adjacent fields of view were tiled together with no
overlap.
Quantitation of signal intensity and surface area of cells from lung
sections. The immunofluorescence was quantified and signal area was
calculated by using Fiji Image J application (downloaded from http://
fiji.sc/). The unprocessed Zeiss confocal images were opened in Fiji
Image J and individual red, green, and blue channels were split.
Subsequently, by use of a drawing toolbar, the desired signal regions
were demarcated and added to ROI Manager in the software. In each
case, the signal intensity and the area were measured for about four to
seven cells from insets. The mean and standard deviation of the values
were calculated and the graphs were plotted with MS-Excel.
RESULTS
GRHL2 expression pattern in embryonic, fetal, and adult
human lung. We have previously characterized GRHL2 ex-
pression patterns at different stages of mouse lung develop-
ment, namely at E9.5, E15.5, and E18.5 and in adult lung, by
immunohistochemistry and immunofluorescence (40). GRHL2
Table 1. List of primary antibodies
Name of Antibody (anti-) Host Catalog Number, Source Dilution
Grainyhead-like 2 (GRHL2) Rabbit HPA004820, Sigma-Aldrich 1:300
E-cadherin (CDH1) Mouse 610182, BD Transduction Laboratories 1:500
Vimentin (clone V-9) Mouse V6630, Sigma-Aldrich 1:200
ATP-binding cassette subfamily A member 3
(ABCA3) (clone 17-H5-24) Mouse WMAB-ABCA3-13, Seven Hills Bioreagents 1:500
p63 (4A4) Mouse sc-8431, Santa Cruz Biotechnology 1:100
-Tubulin4 Mouse MU178-UC, Biogenex 1:100
	-Smooth muscle actin (	-SMA) (CLONE 1A4)
Cy3 conjugated Mouse C6198, Sigma-Aldrich 1:100
NK2 homeobox 1 (NKX2-1), also known as thyroid
transcription factor 1 (TTF-1) Mouse MAB5460, Millipore 1:1000
Forkhead box protein M1 FOXM1 (K-19) Rabbit sc-500, Santa Cruz Biotechnology 1:50
Zinc finger E-box binding homeobox1 (ZEB1) Mouse AMAb90510, Atlas Antibodies, Sweden
CD68 (clone KP1) Mouse 08-0125, Life Technologies Predilute, ready to use
Normal Rabbit IgG sc-2027, Santa Cruz Biotechnology Concentration similar to the respective
primary antibody used
Normal mouse IgG sc-2025, Santa Cruz Biotechnology Concentration similar to the respective
primary antibody used
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Fig. 1. GRHL2 is abundantly expressed in the developing lung epithelium but only appears in lung mesenchyme at week 9. Double staining of Grhl2 and its
target E-cadherin (CDH1) in embryonic lung tissue (A–C), fetal lung tissue (D–F), and normal adult lung tissue (G and H). C=, F=, and I= are insets. C
, F
, and
I
 are enlarged regions of the small box shown in C, F, and I, respectively. Blue arrows show airway epithelium. Open white arrows show mesenchyme and white
arrows show epithelium. Double staining of GRHL2 and alveolar type II epithelial cell marker ABCA3 in fetal lung tissue (J–L) and normal adult lung tissue
(M–O). L= and O= are insets. Insets do not show DAPI for clarity. Scale is 100 m for A–O, 20 m for C=, F=, I=, L=, and O=, and 10 m for C
, F
, and I
.
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is exclusively expressed in mouse lung epithelium at all stages
of normal mouse lung development and is not detected in
mouse lung mesenchyme. Here, in Fig. 1, we show the expres-
sion patterns of GRHL2 in human early fetal (9 wk), late fetal
(week 38), and normal adult lungs (58-yr-old male). In the
early fetal lung (Fig. 1, A–C, C=, and C
) double staining of
GRHL2 and CDH1 showed that GRHL2 is expressed at high
levels in developing epithelium (indicated by blue arrows in
B). We also observed relatively lower GRHL2 expression
signal in the mesenchyme (indicated by open white arrows
in C=). However, double staining of GRHL2 with CDH1 in
normal late fetal (38 week) and adult lung tissues (Fig. 1, D–I,
F=, and I=) showed that GRHL2 is exclusively expressed in
both airway (blue arrow) and alveolar epithelium (white ar-
rows) but is not detected in mesenchyme (white open arrows)
at these stages. These results suggest a dynamic change in the
expression pattern of GRHL2 during normal human lung
development. By double staining of GRHL2 with a type II
AEC surface marker, ATP-binding cassette subfamily A mem-
ber 3 (ABCA3) in fetal (Fig. 1, J–L and L=), and normal adult
human lung tissues (Fig. 1, M–O and O=), we observed that
GRHL2 is expressed in developing alveolar epithelium both at
the fetal stage and also in differentiated alveolar type II cells in
adult lung. It can be noted that, although GRHL2 is expressed
in both airway and alveolar epithelium, ABCA3 is exclusively
expressed only in developing alveolar epithelium (L and L=,
white arrow) and differentiated type II alveolar epithelium (O
and O=, white arrow) but not in airway epithelium (L and L=,
blue arrow). The expression pattern of GRHL2 in human fetal
and adult lung is therefore consistent with our previous find-
ings in mouse lung. The expression pattern of ABCA3 is also
consistent with previous studies (35).
Differential expression pattern of GRHL2 in IPF vs. normal
human lung. We and other researchers have shown that Grhl2
is the predominant member of the Grhl family expressed in
mouse lung epithelium (2, 40). Grhl family members are
epidermal wound healing genes, reported to play an important
role in injury repair (36). We performed immunofluorescence
studies to determine the expression levels and distribution of
GRHL2 in normal human adult vs. IPF lungs. In normal adult
lung (Fig. 2, A–C and C=) GRHL2 signal was observed only in
epithelium but not in mesenchyme. However, to our surprise
we found that in IPF lungs GRHL2 fluorescent signal not only
is intensified in alveolar epithelium (white arrow) but also
appeared ectopically in lung mesenchyme (open white arrow in
F=). Consistent with earlier findings we also observed hyper-
plastic AEC in IPF lung (F=), which were distinct from the
normal cuboidal AEC (C and C=). (Control staining with
isotype IgG in normal and IPF lung data available on request.)
Differential expression pattern of GRHL2 in IPF distin-
guishes at least two subsets of type II alveolar epithelial cells.
We further characterized the expression levels of GRHL2 in
normal and IPF lung by double staining with AEC surface
marker, ABCA3. We observed at least two different subtypes
of AEC in IPF lung sections (Fig. 3, D–F and F=): 1) cells with
bright GRHL2 and ABCA3 fluorescence (shown by white
arrow in Fig. 3, F=), and 2) cells with relatively dim GRHL2
and ABCA3 fluorescence (shown in open white arrow in F=).
However, in normal adult lung section, the fluorescence of
GRHL2 and ABCA3 appeared uniform in normal adult lung
and we did not observe any alternative GRHL2 and ABCA3
fluorescence patterns (Fig. 3, A–C and C=). We also found cells
in the lumen of IPF lung with speckled fluorescence for
GRHL2 but dim ABCA3. The total pixel intensity for GRHL2
Fig. 2. GRHL2 expression is observed in both lung epithelium and mesenchyme of idiopathic pulmonary fibrosis (IPF) lung. GRHL2 Immunofluorescence
staining in normal (A–C) and IPF lung (D–F). C= and F= are insets of their respective images that lack DAPI for clarity. White arrows in C= and F= indicate
epithelial cells whereas open white arrows in F= indicate mesenchyme. Scale bar for A–F is 100 m and for C= and F= it is 20 m.
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fluorescence in the speckled cells was substantially lower than
in cells lining the lumen, which showed strikingly bright
GRHL2 fluorescence intensity. We calculated the average
surface area of the nucleus and the cell based on fluorescence
boundaries of GRHL2 and ABCA3, respectively, which are
shown in Fig. 3H. We found substantial differences between
normal and IPF alveolar cell and nucleus surface areas. This
difference correlated well with increased fluorescence levels in
alveolar cells in IPF vs. normal alveolar cells, suggesting an
increase in detectable levels of both ABCA3 and GRHL2 in
this subset of AEC. We postulated that these two AEC sub-
types in IPF lung may reflect cell-flattening events, as were
observed in our previous studies after knockdown of GRHL2
in lung epithelial MLE15 cells. Such cell-flattening events,
which are related to epithelial plasticity, have been reported
before in IPF (10, 30, 31).
We further explored the distribution of GRHL2 along with
the AEC marker, ABCA3 (Fig. 4, A–C and C=). We observed
cell plasticity events (open white arrow in C=) relating to AEC
flattening at the luminal surface as well as within dense fibrotic
regions of IPF lungs (Fig. 4, D–F and F=), suggesting that these
cell-flattening events are not restricted to epithelial cells that
may be shedding into the lumen. We have previously reported
that, as mouse alveolar type II cells from Sftpc GFP mice
flatten in vitro, levels of GRHL2 and CDH1 drop substantially
(40). By knocking down GRHL2 in lung epithelial MLE15
cells, epithelial markers such as Cldn4 and Cdh1 were also
downregulated (40), as also shown in Fig. 9B. In the present
study, by double staining GRHL2 with CDH1 (Fig. 4, G–I and
I=), we confirmed cell-flattening events (shown in open white
arrows) in IPF lung. We also observed AEC, which were low
for GRHL2 fluorescence in the lumen and lacked CDH1 signal
or showed very low levels of CDH1 fluorescence. This expres-
sion pattern of CDH1 correlated with the expression pattern of
ABCA3. To further evaluate whether these cells were under-
going cell-flattening events, we also double stained GRHL2
Fig. 3. GRHL2 and ABCA3 localization shows 2 subtypes of alveolar type II cells. Double staining of GRHL2 and ABCA3 in normal lung (A–C) and in IPF
lung (D–F). C= and F= are insets of their respective images. In C= and F= white arrow indicates a subtype of alveolar type II cells that show bright GRHL2 and
ABCA3 signals, whereas open white arrows in F= indicate another subtype with lower fluorescence intensity for GRHL2 and ABCA3 signals. Insets do not show
DAPI for clarity. Scale for A–F is 100 m and for C= and F= it is 20 m. Mean area of cells (4–7 in number) from inset F and F= was calculated in G. Mean
gray intensity  area was also calculated from same inset as shown in H. To calculate the intensity we compared cell with high fluorescence intensity for GRHL2
and ABCA3 in IPF with alveolar cells in normal type II cells.
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with mesenchymal markers such as Vimentin (VIM) (Fig. 4,
J–L and L=), 	-smooth muscle actin (	-SMA) (Fig. 4, M–R and
O= and R=), and ZEB1 (Fig. 4, S–U and U=) in IPF lungs. In the
epithelial layer surrounding distal lumen or in collapsing alve-
olar epithelium we observed both GRHL2- and VIM-positive
cells but never detected GRHL2 and 	-SMA-positive cells.
GRHL2- and 	-SMA-positive cells were only found within
certain densely fibrotic regions (Fig. 4, P–R and R=). It should
Fig. 4. Colocalization of GRHL2 with epithelial
and mesenchymal markers in IPF lung suggests
cell-flattening events. Double staining of GRHL2
and ABCA3 (A–F) or CDH1 (G–I) or Vimentin
(VIM; J–I) or 	-smooth muscle actin (	-SMA;
M–R) or ZEB1 (S–U). C=, F=, I=, L=, O=, R=, and U=
are insets of their respective images. White arrow
in F, I=, L=, and O= indicates epithelial nature of
cells whereas open arrow in C=, F=, and I= indicates
cell flattening in collapsing alveolar regions. In R=,
open arrows show myofibroblasts distant from col-
lapsing alveoli. Scale bar for A–U is 100 m and
for C=, F=, I=, L=, O=, R=, and U= it is
20 m.
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also be noted that we observed several cell-flattening events in
alveolar epithelium as shown by open arrows in Fig. 4, C=, F=,
I=, and L=, but rarely in airway epithelium (Fig. 4, L and O).
Double staining of GRHL2 and ZEB1, an activator of EMT
(Fig. 4 S–U and U=) also revealed several fibroblast-like cells
positive for both GRHL2 and ZEB1 (open white arrows in U=)
as well as AEC, which showed only Grhl2 stain but not ZEB1.
There have been recent reports that basal cells may be
involved during lung injury repair and regeneration (28), so we
double stained GRHL2 with -tubulin-4 to observe the distri-
bution of ciliated cells in IPF lung and with p63 (images
available on request) to observe any changes in the distribution
of basal cells. Tiling with confocal imaging of the entire
section was performed. In Fig. 6, we show a representative
image from one section. We did not observe any changes in
distribution of ciliated cells in airway epithelium, as indicated
by the red arrow, nor did we observe any expansion of basal
cells as indicated by red arrows. We also did not observe any
Fig. 5. Colocalizaton of GRHL2 with epi-
thelial and mesenchymal markers in serial
sections shows cell-flattening events. Dou-
ble staining of GRHL2 and CDH1 (A–C,
G–I, and M–O). Double staining of GRHL2
and VIM in IPF lung is shown in (D–F, J–L,
and P–R. C=, F=, L=, O=, and R= are insets of
their respective images. In C=, I=, and O=
white arrow indicates a subtype of epithelial
cells that show bright GRHL2 and CDH1
signals, whereas in F=, L=, and R= white open
arrow indicates another subtype that has
both CDH1 and VIM signals. Insets do not
show DAPI for clarity. Scale bar for A–R is
100 m and for C=, F=, I=, O=, and R= it is
20 m.
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p63-positive cells in any other distal areas of the IPF sections
and observed only limited cell-flattening events in more prox-
imal airways, corroborating previous histological studies.
To ascertain that cell-flattening events occurred within the
same cell, we performed immunofluorescence of GRHL2 with
CDH1 or with VIM in serial sections. We performed tiling of
the entire IPF lung sections and found several interesting
pathophysiological features. Figure 5 shows hyperplastic AEC
lining honeycomb-like structures in IPF lung. We show two
sets of regions, A–I and J–R, in which GRHL2-CDH1 and
GRHL2-VIM double staining have been performed in IPF lung
sections. The first two sets of panels, A–F and G–L, are from
the same region but show different insets to illustrate cells in
the lumen that express both CDH1 (white arrows) and VIM
(open white arrow), suggesting cell plasticity events related to
cell flattening. In M–R we show another region where cells in
the AEC layer show both epithelial (white) and mesenchymal
(open white arrows) markers, suggesting that cell plasticity
Fig. 6. Grhl2 distribution in bleomycin-induced injury model does not show an overlap with 	-SMA. A: double staining of Grhl2 and its target E-cadherin (Cdh1)
at different time points during bleomycin injury model (A–D) and with Grhl2 and 	-SMA (E–H). A=-H= are insets of A–H, respectively. Scale bar for A–H is
100 m, and for A= to H= it is 10 m.
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events also occur in the epithelial layer. Another important feature
was altered distribution of CDH1 in hyperplastic AEC, with
excessive distribution of CDH1 in the basal region (white arrow in
Fig. 5O=) rather than the lateral region. This was suggestive of
alteration of apical-to-basolateral polarity and disruption of adhe-
rens junctions between AEC. These results collectively show
cell-flattening events within hyperplastic AEC in IPF.
GRHL2 expression pattern in mouse models of fibrosis
reveals distinct differences from IPF. Three mouse models of
pulmonary fibrosis were compared for Grhl2 expression pat-
tern. These were 1) IP bleomycin-induced lung injury (9), 2)
spontaneously occurring pulmonary fibrosis in the HPS1/2
model (24), and 3) overexpression of activated form of Foxm1
followed by irradiation, which leads to pulmonary fibrosis (4).
As shown in Fig. 6, in the IP bleomycin model we examined
the expression of Grhl2 along with Cdh1 (A–D) or with
	-SMA (E–H) during the course of injury at days 7, 28, 70, and
140. At day 28, when the fibrotic response was at its peak, we
observed a higher number of AEC showing more Grhl2 fluo-
rescence (white arrows in insets) and also for its target Cdh1.
The increased fluorescence intensity for Grhl2 was also ob-
served at day 70 when the fibrotic response starts to resolve,
whereas by day 140, when there is no longer fibrosis, the
fluorescence intensity of Grhl2 appeared to be back at basal
levels. Grhl2 and 	-SMA double staining during the course of
bleomycin injury (Fig. 6, E–H) showed no overlap of Grhl2
expression pattern with 	-SMA expression. At day 28, when
the fibrotic response was at its peak, we were unable to observe
two distinct populations of AEC based on fluorescence inten-
sity of Grhl2. AEC cell shape appeared altered within fibrotic
regions. Gene expression analysis of lung from various time
points of injury and repair vs. controls (treated with PBS) did
not show significant changes in Grhl2 levels (data not shown).
In HPS1/2 mutants, we double stained Grhl2 with its target
Cdh1 and observed changes in expression level and their
pattern compared with wild-type lung (Fig. 7). We observed
that the AEC (shown by white arrow) appear larger with
altered morphology consistent with previous observations (24).
We also observed substantial increases in Grhl2 and Cdh1
fluorescence levels in HPS1/2 mice (C=) compared with wild-
Fig. 7. Grhl2 expression pattern in double-mutant HPS1 and HPS2 (HPS1/2) lung tissue is altered. Double staining of Grhl2 and its target (Cdh1) in normal adult
lung tissue (A–C) and HPS1/2 lung tissue (D–F). C= and F= are insets. White arrow in C= and F= indicate epithelial cells. Insets do not show DAPI for clarity.
Scale bar for A–F is 100 m and for C= and F= it is 20 m. G: gene expression analysis of Grhl2 and Cdh1 was performed in triplicates from the same paraffin
sections after recovery of RNA as described in MATERIALS AND METHODS. Gapdh was used as endogenous controls.
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type (Fig. 7F). Gene expression analysis from the same paraf-
fin sections showed increased expression of Grhl2 and Cdh1
(Fig. 7G), thus validating the immunofluorescence signals.
In radiation-induced pulmonary fibrosis with Foxm1 misex-
pression, we double stained Grhl2 and Cdh1 (Fig. 8, A–C and
C=) and Grhl2 and 	-SMA (Fig. 8, D–F and F=). In this model
we observed a higher fibrotic response than that noticed fol-
lowing IP bleomycin. Airway epithelium, as shown in serial
sections in Fig. 8, C and F, exhibited high fluorescence signals
for Grhl2 and Cdh1 but no signal for 	-SMA. Several collaps-
ing alveoli were observed within fibrotic regions with differ-
ential Grh2 fluorescence intensities in AEC. Epithelial cells
with intense fluorescence for Grhl2 are shown in white arrow
in Fig. 8C=. AEC in which Grhl2 fluorescence intensity is very
low are shown with open white arrows in Fig. 8F=). There were
several collapsing alveoli, which had completely lost epithelial
markers, Grhl2 and Cdh1, but were expressing myofibroblast
marker, 	-SMA (shown with blue arrows in Fig. 8, B and E).
Gene expression analysis of lung samples did not show signif-
icant changes in levels of Grhl2 (data not shown).
Grhl2’s roles in epithelial integrity and epithelial cell
plasticity. From the immunofluorescence studies in human IPF
we speculated that GRHL2 expression level must be compro-
mised within areas of fibrotic tissue, since in IPF alveolar
spaces appear to be overwhelmed with fibroblasts and myofi-
broblasts. Hence we compared the levels of Grhl2 in 11 IPF
specimens with eight control lung donor specimens (Fig. 9A).
Consistent with the above speculation, we observed signifi-
cantly decreased levels of GRHL2 expression within fibrotic
tissue.
To further demonstrate that Grhl2 indeed has a role in
epithelial cell plasticity and to validate our fluorescence inten-
sity and distribution data in IPF lung sections we performed
knockdown vs. overexpression studies of Grhl2 in the cuboidal
alveolar epithelial type II-like MLE15 cell line compared with
mesenchymal-like E10 cells, respectively (Fig. 9). We had
previously observed downregulation of epithelial genes after
knockdown of Grhl2 in mouse alveolar MLE15 cells (40).
Here, we also consistently observed downregulation of epithe-
lial markers when Grhl2 was knocked down by using another
shRNA (pKLO series) (Fig. 9A). However, EMT markers such
as Vim and Zeb1 were upregulated, but 	-SMA was not
detected in MLE15 cells. We had previously concluded that
Grhl2 knockdown in MLE15 cells results in cell flattening by
showing phalloidin staining (40). In the present work, by using
a different Grhl2-shRNA to knock down Grhl2, we observed
even more pronounced cell-flattening events in MLE15 cells
(Fig. 9C). We had previously shown that E10 cells do not
express Grhl2 and also had shown that overexpression of Grhl2
in flat E10 cells resulted in a less flattened morphology (40).
Here, in Fig. 9D we confirmed that GRHL2 is expressed in E10
cells transduced with CMV-Grhl2-UBC-GFP vector, by im-
munofluorescence staining. We also now show that overex-
pression of Grhl2 in E10 cells leads to increased CDH1
expression but no significant downregulation of mesenchymal
genes (Fig. 9E). We did in fact observe a modest increase in
mesenchymal markers, suggesting that E10 cells can express
markers of both epithelial and mesenchymal lineages in the
presence of high levels of Grhl2.
Fig. 8. Grhl2 expression pattern in serial section of lung from irradiation mouse model. Double staining of Grhl2 and Cdh1 is shown in A–C and C=. Double
staining of Grhl2 and 	-SMA is shown in D–F and F=. C= and F= are insets. White arrows in C= and open arrows in F= indicate alveolar epithelial cells (AEC)
in same region is undergoing cell-flattening events. Blue arrows show collapsed alveolar spaces with AEC showing low Grhl2 fluorescence intensity. Orange
arrows in C and F show airway epithelium with high GRHL2 and Cdh1 signal but no 	-SMA signal. Scale bar for A–F is 100 m, and for C= and F= it is
20 m.
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DISCUSSION
Herein we have discovered some interesting pathophysio-
logical differences between human IPF lung and three mouse
models of pulmonary fibrosis: 1) IP bleomycin-induced model,
2) spontaneously occurring pulmonary fibrosis in HPS1/2 mu-
tant mice, and 3) radiation-induced fibrosis in which the
activated form of Foxm1 is misexpressed. We also showed for
the first time evidence of involvement of GRHL2 in IPF.
We observed that GRHL2 distribution and expression levels,
based on immunofluorescence, were clearly altered in IPF lung
compared with normal adult lung. Previously it has been
demonstrated by gene expression studies that IPF lung is
characterized by aberrant activation of developmental path-
ways including signaling pathways involved in epithelium and
mesenchymal cross talk and epithelial plasticity (18, 32).
Hence we thought it important to characterize and compare the
distribution of GRHL2 during lung development as well as in
adult human lung. This analysis showed interesting differences
in the distribution of GRHL2 in embryonic, fetal, and adult
human lung.
Although we observed high expression of GRHL2 based on
fluorescence intensity in embryonic and fetal tissues, the flu-
orescence levels were relatively diminished in human adult
lung epithelium. This developmentally dynamic expression
pattern of GRHL2 was validated in human lung by gene
expression analysis at the fetal stage (week 20) vs. normal
adult lung as well as being confirmed at several stages of
mouse lung development (data available on request).
Within IPF lung we further observed both high fluorescent
intensity of GRHL2 in collapsing alveolar epithelium, together
with a surprising ectopic expression in mesenchyme, rather
similar to the expression pattern observed at human embryonic
weeks 9–11. We speculate that increased fluorescent intensity
of GRHL2 in lung epithelium and mesenchyme may reflect
active tissue remodeling in IPF. Thus altered GRHL2 distribu-
tion and increased fluorescence intensity may have the future
potential to be used as a possible diagnostic biomarker in
combination with other putative signatures for IPF. Develop-
mental programs are also activated in cancers during tumor
progression and metastatic events. GRHL2 has been associated
with breast cancer metastasis and tumor progression and also
with other cancers (7, 8, 13, 19, 21, 37, 42–44). A similar
systematic distribution and expression analysis of GRHL2 in
lung cancer has yet to be performed.
A current model of IPF suggests that compromised epithelial
integrity is a major component of pathogenesis and may in fact
Fig. 9. Altered expression level of GRHL2
in human IPF in vitro manipulation of Grhl2
in mouse epithelial cells lines highlights the
functional role of GRHL2 in IPF. A: GRHL2
expression level in IPF patients showed
substantial decrease compared with non-IPF
donors. GAPDH was used as endogenous
control for normalization. B: epithelial and
mesenchymal expression level in Grhl2
knockdown studies in MLE15 cells showed
decrease in epithelial genes such as Cdh1
and Cldn4 but showed increased expression
of Vim and Zeb1. C: cell morphology of
MLE15 cells transduced with nonsilencing
(Nonsilence) and Grhl2 shRNA. Grhl2
knockdown in MLE15 shows cell flattening
of MLE15 after 92 h of incubation. D: Grhl2
staining in E10 cells transduced with CMV-
GRHL2-UBC-GFP to show that stable trans-
fections and expression of Grhl2. E: overex-
pression of Grhl2 in E10 cells showed up-
regulation of Grhl2 and Cdh1 with modest
increase in mesenchymal genes. E10 cells
were either transduced with lentivirus con-
taining CMV-Grhl2-UBC-GFP (E10-Grhl2)
or with empty vector (CMV-dsred-UBC-
GFP). GRHL2 expression studies were per-
formed with 11 IPF patients and 8 non-IPF
donors. Grhl2 knockdown and overexpres-
sion studies were performed in triplicate.
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initiate the fibrotic response (16, 20, 29, 34, 39). This model is
supported by studies demonstrating that pulmonary fibrosis can
occur following the ablation of factors that normally maintain
epithelial integrity without any preceding inflammation (25,
39, 45). The model suggests that chronic injury results in the
activation of a subset of bronchial and AEC that become
hyperplastic with enlarged cell shape, whereas another subset
of alveolar type II cells that are sensitive to chronic injuries
undergo cell-flattening events. Herein, and as summarized in
the working model in Fig. 10, we were able to document these
two subsets of AEC based on relative fluorescent intensities of
GRHL2 and ABCA3. This model of IPF pathogenesis also
suggests that a compromise in epithelial integrity during IPF
results in cell flattening of AEC. Previously we showed that
knockdown of GRHL2 leads to disruption of epithelial integ-
rity, with cell flattening of AEC-like MLE15 cells, which
suggested a functional role for Grhl2 in IPF. Now, by compar-
ing GRHL2 fluorescence levels with epithelial marker CDH1
vs. mesenchymal markers VIM and SMA, we identified actual
cell-flattening events in human AEC in IPF.
Furthermore, by analyzing the expression level of epithelial
vs. mesenchymal genes in Grhl2 knockdown vs. overexpres-
sion studies, we provide further evidence of its role in cell
plasticity in alveolar MLE15 epithelial cells. In addition, a
decreased level of Grhl2 transcripts in fibrotic tissue from IPF
patients is consistent with the notion that epithelial integrity-
maintaining genes are downregulated in the fibrotic areas of
IPF lung and are likely to be important in the pathogenesis of
the disease. It should be further noted that the overall decreased
levels of Grhl2 in fibrotic tissue may not represent the elevated
expression pattern of Grhl2 specifically within collapsing epi-
thelium. Future studies employing laser capture microscopy of
activated AEC followed by single cell gene expression analysis
will be required to settle this issue.
Several signaling pathways are activated in IPF and mouse
models of pulmonary fibrosis, like Notch, Wnt/ catenin, and
AKT/PI3 kinase signaling (32). In our previous work on
knockdown studies of Grhl2 in AEC-like MLE15 cells we
showed by microarray and with further validation by qRT-PCR
that Notch1 levels were compromised (40). We have also
performed chromatin immunoprecipitation (ChIP) DNA deep
sequencing analysis in AEC-like MLE15 cells and isolated
lung buds at E11.5 to show that GRHL2 may regulate the
above-mentioned pathways (S. Varma, unpublished data), giv-
ing us a possible further clue to its functional role in IPF and
other lung diseases. The TGF- signaling pathway, which is
crucial in pathogenesis of IPF and which also can induce AEC
flattening events, is known to be associated with the GRHL2
transcriptional regulatory network (8). In fact, GRHL2 can
negatively regulate the TGF- pathway by targeting down-
stream factors such as ZEB1 (8). In recent work by Gao et al.
(15), several direct targets of GRHL2 were determined in
human mucociliary epithelium by integrating GRHL2 ChIP
sequencing and differential expression analysis by RNA deep
sequencing. Thus there is a considerable amount of evidence
emerging both from our work presented here as well as from
that of others supporting a putative functional role of GRHL2
in pathogenesis IPF and other lung injuries.
In this study both bleomycin-induced fibrosis and the spon-
taneous HPS1/2 fibrosis model showed similarities to IPF in
terms of increased Grhl2 fluorescence levels in AEC, suggest-
ing a common epithelial wounding response. However, there
was an important difference in that detectable levels of Grhl2
were only found within the mesenchyme of IPF lungs, but not
in these mouse models of pulmonary fibrosis. We also did not
find double-positive cells for Grhl2 and mesenchymal markers
in these mouse models, suggesting that cell-flattening events
may be occurring in mouse lung injury models and that this
may be an important difference with what is happening in
human IPF.
Interestingly, the radiation-induced fibrosis mouse model, in
which an activated form of Foxm1 is misexpressed in AEC, did
Fig. 10. Proposed model of progression of morphological changes in AECs in human IPF. On the basis of our present findings and information from the literature,
we propose the following model of progression of morphological changes in AECs in IPF. Resting AEC in normal adult express low levels of GRHL2 (light
red color in the nucleus) and CDH1 (shown at the junction in purple). Chronic injury due to environmental factors such as smoking and other unknown factors
activates AECs, which release excessive amounts of profibrotic mediators, become bigger in size, and express high levels of GRHL2 (shown by red nucleus)
and ABCA3 (shown as green cytoplasm). Meanwhile another subset of AEC found in human IPF, which are seen both in epithelial lumen or in dense fibrotic
regions, undergo cell-flattening events, characterized by expression of low levels of punctate GRHL2 (shown in diffused red color) in the nucleus with little or
no detection of CDH1, but that express VIM (shown as pink color in the cytoplasm). GRHL2 and 	-SMA double-positive cells are not found in epithelial lumen
or regions close to collapsing alveoli. These double-positive cells, which appear myofibroblast-like, are only found in dense fibrotic regions and may be a late
event in the progression of IPF. Bottom panel summarizes our observations made for expression pattern of various markers of epithelium and mesenchyme (↔
basal expression level; 2 lower expression; 1 high expression; 11 very high expression; 22 very low expression;  nondetectable or absent).
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show an overlap of epithelial and mesenchymal markers within
the same cells, thus enforcing the idea that cell-flattening
events can occur in AECs under certain specific circumstances.
Moreover, our observation of two subsets of AEC based on
Grhl2 fluorescence level and its presence in flattened cells
suggests that this irradiation model may be a closer replica of
the pathogenesis of human IPF.
In summary, this report provides evidence in favor of the
epithelial initiation model of IPF and supports the concept that
epithelial injury and subsequent disintegrity of the epithelium
may be the most crucial early step during the pathogenesis of
IPF. Our work also sheds light on the controversial subject of
epithelial-mesenchymal plasticity, by showing that cell flatten-
ing of AEC does indeed exist and that this may contribute to
formation of fibrotic foci in human IPF. We have also de-
scribed a novel distribution pattern of GRHL2 in early embry-
onic lung development as well as in fetal and adult human
lung. Moreover, we show important differences between most
mouse and human models of lung fibrosis with regard to Grhl2
patterns of expression.
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